Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Nurix Therapeutics, Inc. (NRIX)
|
Add to portfolio |
|
|
|
| Price: |
$28.84
| | Metrics |
| OS: |
48.2
|
M
| |
-61
|
% ROE
|
| Market cap: |
$1.39
|
B
| |
-74
|
% ROIC
|
|
Net cash:
|
$309
|
M
| |
$6.40
|
per share
|
|
EV:
|
$1.08
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($165)
|
M
| |
|
|
| EPS |
($2.97)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Nov-30-22 | Nov-30-21 | Nov-30-20 | Nov-30-19 | Nov-30-18 |
| Revenues | 184.5 | 29.8 | 17.8 | 31.1 | 40.5 |
| Revenue growth | 520.2% | 66.9% | -42.7% | -23.2% | |
| Cost of goods sold | 222.5 | 0.0 | 0.0 | 0.0 | 47.2 |
| Gross profit | -38.0 | 29.8 | 17.8 | 31.1 | -6.7 |
| Gross margin | -20.6% | 100.0% | 100.0% | 100.0% | -16.5% |
| Research and development | | 116.4 | 66.5 | 45.0 | |
| General and administrative | 38.0 | 31.2 | 16.3 | 8.3 | 6.7 |
| EBIT | -183.9 | -117.9 | -65.0 | -22.2 | -9.7 |
| EBIT margin | -99.7% | -396.3% | -364.7% | -71.5% | -24.0% |
| Pre-tax income | -180.4 | -117.1 | -63.8 | -21.5 | -8.9 |
| Income taxes | 0.0 | 0.1 | -20.5 | 0.2 | 0.5 |
| Tax rate | 0.0% | | 32.2% | | |
| Net income | -180.4 | -117.2 | -43.2 | -21.7 | -9.4 |
| Net margin | -97.8% | -393.9% | -242.7% | -69.7% | -23.3% |
| |
| Diluted EPS | ($3.71) | ($2.73) | ($2.76) | ($6.59) | ($3.35) |
| Shares outstanding (diluted) | 48.6 | 42.9 | 15.7 | 3.3 | 2.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|